Aster DM Quality Q1 FY27 Earnings Call Analysis

- EBITDA margin target of 24%-25% expected within 2-3 years post-merger, with a good exit from FY27 and reaching targets between FY28-FY29. - Synergies targeted to contribute 10%-15% of FY24 proforma EBITDA incrementally, with significant realization expected starting FY27 onwards. - Revenue growth driven by volume expansion, enriched case mix, and higher ARPP, with mature units growing 19% YoY and emerging units showing 63% revenue growth. - EBITDA expected to grow through operational leverage, cost efficiencies, and scale, with emerging units’ EBITDA margin expanding to 12.4%. - Medical Value Travel (MVT) business targeted to grow over 50% CAGR, moving from low single digits to mid-single and then double-digit contribution over time. - Strong clinical platform and brownfield expansion pipeline to sustain growth momentum, with over 4,170 beds addition planned in next 3-4 years. Overall, the company is confident of delivering long-term value with robust operating earnings growth and margin expansion.

The transcript provided from the Aster DM Quality Care Limited Q1 FY27 Earnings Conference Call does not explicitly mention the current or expected order book or pending orders. The discussion primarily focuses on: - EBITDA performance and hospital maturity categories. - Expansion plans including bed additions and new hospital projects (e.g., Bhubaneswar, Raipur cancer center, Kottayam, Nagercoil, Banjara Hills). - Financial performance highlights including revenue and EBITDA growth. - Strategy on clinical programs and geographical focus. - Brownfield and greenfield capacity additions totaling over 4,170 beds planned over the next 3-4 years. No specific data or figures related to order book or pending orders are provided in the available transcript pages. If you need detailed order book insights, it may require direct data from company financial disclosures or specific management commentary.